Literature DB >> 3956591

Studies on vascular smooth muscle cells and dermal fibroblasts in collagen matrices. Effects of heparin.

H P Ehrlich, T R Griswold, J B Rajaratnam.   

Abstract

The incorporation of such tissue-cultured mesenchymal cells as bovine vascular smooth muscle cells (SMS) and human dermal fibroblasts (DF) in a collagen matrix results in the reorganization and distortion of that matrix. A 2 ml collagen matrix populated by 55 000 bovine SMC and having a surface area of 800 mm2 will be reduced to 226 mm2 by 48 h. Under identical conditions, a lattice populated by 55 000 DF will achieve an area of 78 mm2 at 48 h. DF are thus more efficient at reducing the size of a collagen lattice by the process of lattice contraction. Bovine SMC proliferate in a collagen matrix; human DF do not. DF in a collagen matrix have a more elongate morphology than SMC. Actin cytoplasmic filaments were studied using the specific F-actin staining reagent, Rhodamine-phalloidin. DF in collagen matrix exhibit diffuse cytoplasmic staining while, in monolayer, they display prominent staining stress fibers. SMC in monolayer and in matrices show stained clumps at the periphery of the cell. The addition of 200 U/ml heparin to SMC eliminates those actin aggregates and causes the formation of stress fibers. It also causes stress fibers to form in dermal fibroblasts in a collagen lattice. However, the elongation and spreading--and the formation of stress fibers brought about by heparin--lead to an inhibition of lattice contraction. Heparin effectively inhibits cell-mediated lattice contraction in SMC and DF, and it also causes the formation of cytoplasmic stress fibers.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3956591     DOI: 10.1016/0014-4827(86)90462-3

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  12 in total

1.  Tissue engineering science: consequences of cell traction force.

Authors:  R T Tranquillo; M A Durrani; A G Moon
Journal:  Cytotechnology       Date:  1992       Impact factor: 2.058

2.  Differences in the mechanism of collagen lattice contraction by myofibroblasts and smooth muscle cells.

Authors:  J C Dallon; H Paul Ehrlich
Journal:  J Cell Biochem       Date:  2010-10-01       Impact factor: 4.429

3.  Contraction of collagen by human fibroblasts and keratinocytes.

Authors:  J M Souren; M Ponec; R van Wijk
Journal:  In Vitro Cell Dev Biol       Date:  1989-11

4.  A comparative study of paediatric thermal burns treated with topical heparin and without heparin.

Authors:  T S Venkatachalapathy
Journal:  Indian J Surg       Date:  2012-10-05       Impact factor: 0.656

5.  Heparin modulates the composition of the extracellular matrix domain surrounding arterial smooth muscle cells.

Authors:  A D Snow; R P Bolender; T N Wight; A W Clowes
Journal:  Am J Pathol       Date:  1990-08       Impact factor: 4.307

6.  Heparin reduced mortality and sepsis in severely burned children.

Authors:  G J Zayas; A M Bonilla; M J Saliba
Journal:  Ann Burns Fire Disasters       Date:  2007-03-31

7.  A comparative study of burns treated with topical heparin and without heparin.

Authors:  T S Venakatachalapathy; S Mohan Kumar; M J Saliba
Journal:  Ann Burns Fire Disasters       Date:  2007-12-31

8.  Modulation of collagen gel contraction by decorin.

Authors:  K Bittner; C Liszio; P Blumberg; E Schönherr; H Kresse
Journal:  Biochem J       Date:  1996-02-15       Impact factor: 3.857

9.  Epidermal growth factor and transforming growth factor alpha regulate extracellular matrix production by embryonic mouse palatal mesenchymal cells cultured on a variety of substrata.

Authors:  Michael James Dixon; David Foreman; Seth Schor; Mark William; James Ferguson
Journal:  Rouxs Arch Dev Biol       Date:  1993-12

10.  Characterization of engineered tissue development under biaxial stretch using nonlinear optical microscopy.

Authors:  Jin-Jia Hu; Jay D Humphrey; Alvin T Yeh
Journal:  Tissue Eng Part A       Date:  2009-07       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.